
Ocugen, Inc. (OCGN) Stock Forecast & Price Target
Ocugen, Inc. (OCGN) Analyst Ratings
Bulls say
Ocugen is a promising company with a strong pipeline of gene and cell therapies and vaccines, particularly in the field of retinal diseases. With a recent debt offering, the company expects to have ample cash on hand to support its research and development efforts. Despite clinical risk and potential intellectual property challenges, the company's positive clinical data for OCU410 and plans for a Phase 3 study in 3Q26 position it for potential success.
Bears say
Ocugen is a biopharmaceutical company with promising pipeline candidates targeting multiple gene therapies for retinal diseases. However, the company faces standard risks in the biotech industry, as well as specific risks related to regulatory approval and potential competition from other companies. While the potential for successful development and commercialization of their therapies could lead to significant upside for the company, there are also potential risks and uncertainties that could impact their success, resulting in a negative outlook.
This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.
Ocugen, Inc. (OCGN) Analyst Forecast & Price Prediction
Start investing in Ocugen, Inc. (OCGN)
Order type
Buy in
Order amount
Est. shares
0 shares